Sana Biotechnology Inc (SANA) concluded trading on Wednesday at a closing price of $5.14, with 6.27 million shares of worth about $32.24 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 76.03% during that period and on July 23, 2025 the price saw a gain of about 5.54%. Currently the company’s common shares owned by public are about 225.46M shares, out of which, 125.43M shares are available for trading.
Stock saw a price change of 18.71% in past 5 days and over the past one month there was a price change of 97.69%. Year-to-date (YTD), SANA shares are showing a performance of -11.38% which increased to 215.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.26 but also hit the highest price of $7.30 during that period. The average intraday trading volume for Sana Biotechnology Inc shares is 4.58 million. The stock is currently trading 35.64% above its 20-day simple moving average (SMA20), while that difference is up 76.85% for SMA50 and it goes to 89.56% higher than SMA200.
Sana Biotechnology Inc (NASDAQ: SANA) currently have 225.46M outstanding shares and institutions hold larger chunk of about 51.65% of that.
The stock has a current market capitalization of $1.16B and its 3Y-monthly beta is at 1.90. It has posted earnings per share of -$0.88 in the same period. It has Quick Ratio of 3.40 while making debt-to-equity ratio of 0.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SANA, volatility over the week remained 9.58% while standing at 9.66% over the month.
Stock’s fiscal year EPS is expected to rise by 34.68% while it is estimated to increase by 6.84% in next year. EPS is likely to grow at an annualized rate of 14.13% for next 5-years, compared to annual growth of -10.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on July 03, 2025 offering an Overweight rating for the stock and assigned a target price of $12 to it. Coverage by Citizens JMP stated Sana Biotechnology Inc (SANA) stock as a Mkt outperform in their note to investors on March 18, 2025, suggesting a price target of $5 for the stock. Stock get a Mkt perform rating from JMP Securities on November 05, 2024.
